Related Experiment Video
Updated: Sep 10, 2025

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
Factors Influencing COVID-19 Viral Clearance: Implications for Vaccination and Antiviral Therapy
Jia Zeng1, Heping Xu1, Shuai Luo1
1Emergency Department of Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan, 570311, People's Republic of China.
Background:
Understanding the factors influencing viral clearance in hospitalized COVID-19 patients, including vaccination status and antiviral therapy, is critical for optimizing clinical management.
Methods:
1,424 hospitalized COVID-19 patients retrospectively included from four tertiary hospitals in Hainan Province between March and December 2022. Viral clearance was defined as the interval from hospital admission to the first of two consecutive RT-PCR tests with Ct values ≥35. Clinical data, vaccination history, and antiviral treatment were collected. A generalized linear mixed model and Robust regression were used to assess viral clearance dynamics and their predictors.
Results:
Delayed viral clearance was independently associated with advanced age (p < 0.001), male sex (p = 0.006), hypertension (p < 0.001), coronary heart disease (p = 0.004), ICU admission (p < 0.001), and mechanical ventilation (p < 0.001).Patients receiving ≥2 inactivated vaccine doses had significantly higher baseline Ct values (median 29.75 vs 28.75, p = 0.014), shorter time to viral negativity (6.3 vs 7.4 days, p < 0.001), and reduced hospital stay (11.2 vs 12.7 days, p < 0.001). Among these, patients vaccinated ≥360 days prior had shortest negative conversion time (5.6 days) and shortest hospitalization (10.3 days).Antiviral therapy with Nirmatrelvir-ritonavir (N/R) accelerated viral clearance more effectively than Azvudine (2.29 vs 1.82 Ct/day, p = 0.045) and no antiviral treatment (1.88 Ct/day, p = 0.041), Although NAT-treated patients achieved viral negativity more rapidly (6.2 days, p = 0.013), N/R demonstrated superior clearance rate. Hospital stays were shorter with N/R than Azvudine (12.1 vs 13.5 days, p = 0.015).
Conclusion:
Viral clearance dynamics in hospitalized COVID-19 patients are influenced by age, comorbidities, vaccination, and antiviral treatment. Administration of ≥2 inactivated vaccine doses-especially ≥360 days apart-and early N/R therapy may accelerate viral clearance and reduce hospital stay.
Related Concept Videos
Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Microorganisms in Medicine and Therapeutics
Myocarditis III: Medical Management
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Retrovirus Life Cycles
Factors Affecting Drug Response: Overview

